期刊
TOXICS
卷 9, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/toxics9100229
关键词
paclitaxel; CIPN; paclitaxel-induced peripheral neuropathy; neurotoxicity; neuropathy; taxol
Peripheral neuropathy is a common side effect of chemotherapy, affecting up to 60% of cancer patients. Paclitaxel induces neuropathy in gynecological and urological cancer patients, leading to cell death and affecting both central and peripheral nervous system cells. Symptoms include pain and numbness in hands and feet, with pathomechanisms involving axonal damage and disrupted axonal transport.
Peripheral neuropathy is one of the most common side effects of chemotherapy, affecting up to 60% of all cancer patients receiving chemotherapy. Moreover, paclitaxel induces neuropathy in up to 97% of all gynecological and urological cancer patients. In cancer cells, paclitaxel induces cell death via microtubule stabilization interrupting cell mitosis. However, paclitaxel also affects cells of the central and peripheral nervous system. The main symptoms are pain and numbness in hands and feet due to paclitaxel accumulation in the dorsal root ganglia. This review describes in detail the pathomechanisms of paclitaxel in the peripheral nervous system. Symptoms occur due to a length-dependent axonal sensory neuropathy, where axons are symmetrically damaged and die back. Due to microtubule stabilization, axonal transport is disrupted, leading to ATP undersupply and oxidative stress. Moreover, mitochondria morphology is altered during paclitaxel treatment. A key player in pain sensation and axonal damage is the paclitaxel-induced inflammation in the spinal cord as well as the dorsal root ganglia. An increased expression of chemokines and cytokines such as IL-1 beta, IL-8, and TNF-alpha, but also CXCR4, RAGE, CXCL1, CXCL12, CX3CL1, and C3 promote glial activation and accumulation, and pain sensation. These findings are further elucidated in this review.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据